Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-07-03
Last Posted Date
2018-04-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
15
Registration Number
NCT01891968
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection

First Posted Date
2013-06-07
Last Posted Date
2017-03-23
Lead Sponsor
Medical University of Vienna
Target Recruit Count
44
Registration Number
NCT01873157
Locations
🇦🇹

Medical University of Vienna, Department of Nephrology and Dialysis, Vienna, Austria

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

First Posted Date
2013-05-29
Last Posted Date
2024-11-28
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
1087
Registration Number
NCT01863550
Locations
🇺🇸

FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States

🇺🇸

Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States

🇺🇸

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States

and more 913 locations

Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2013-05-27
Last Posted Date
2017-09-21
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
3
Registration Number
NCT01863004
Locations
🇨🇭

Neuromuskuläres Zentrum, Universitätsspital Basel, Basel, Switzerland

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

First Posted Date
2013-05-23
Last Posted Date
2024-07-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
15
Registration Number
NCT01861314
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

First Posted Date
2013-05-07
Last Posted Date
2018-09-19
Lead Sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Target Recruit Count
121
Registration Number
NCT01848132
Locations
🇪🇸

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain

🇪🇸

Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

🇪🇸

Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain

and more 18 locations

Desensitization With Bortezomib Before a Living Kidney Donation

First Posted Date
2013-04-29
Last Posted Date
2016-09-29
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
10
Registration Number
NCT01842074
Locations
🇫🇷

Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital, Le KREMLIN-BICETRE, France

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-04-16
Last Posted Date
2020-08-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
17
Registration Number
NCT01833143
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

First Posted Date
2013-04-09
Last Posted Date
2020-01-10
Lead Sponsor
Sellas Life Sciences Group
Target Recruit Count
22
Registration Number
NCT01827137
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath